Omixon Announce French Tender Victory

Omixon today announce that their flagship Holotype HLA assay and software solution for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Etablissement Français du Sang (the French National Blood Service, EFS). Omixon won a two-year competitive tender worth €6.5m,...

 

Read more

Happy Holidays!

Here we are again approaching the holiday season and rounding out another amazing year. So much has happened at Omixon this year and we are very proud to say our company and our role as experts in fostering the adoption of NGS for HLA has grown so much with the...

 

Read more